SAB Biotherapeutics, Inc. (SABSW)
SABSW Stock Price Chart
Explore SAB Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze SABSW price movements and trends.
SABSW Company Profile
Discover essential business fundamentals and corporate details for SAB Biotherapeutics, Inc. (SABSW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Oct 2021
Employees
63.00
CEO
Samuel J. Reich
Description
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
SABSW Financial Timeline
Browse a chronological timeline of SAB Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 13 Aug 2025
EPS came in at -$1.09 falling short of the estimated -$0.80 by -36.93%.
Earnings released on 9 May 2025
EPS came in at -$0.56 .
Earnings released on 30 Sept 2023
EPS came in at -$0.10 , while revenue for the quarter reached $1.27M .
Earnings released on 30 Jun 2023
EPS came in at -$0.14 , while revenue for the quarter reached $85.52K .
Earnings released on 31 Mar 2023
EPS came in at -$0.15 , while revenue for the quarter reached $581.10K .
Earnings released on 31 Dec 2022
EPS came in at -$0.18 , while revenue for the quarter reached $17.55M .
SABSW Stock Performance
Access detailed SABSW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.